ENGN
Engene Therapeutics
$1.76
−$0.06 (−3.3%)Jul 27, 2026
Key metrics
The numbers that frame ENGN today
- Market cap
- $117.90M
- P/E (TTM)
- -0.9
- EV / FCF
- -1.1
- ROIC
- -50%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $1.40
- 52wk High
- $12.25
Growth
Revenue and earnings trend for ENGN
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about ENGN
Is Engene Therapeutics a good buy?
No. Engene Therapeutics has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks excellent, which supports the long-term business case, but that is not enough to offset the weak setup. We think Engene Therapeutics is selling at a very high price.
What is the market capitalization of ENGN?
Engene Therapeutics's market capitalization is $117.90M.
What is the P/E ratio for ENGN stock?
Engene Therapeutics's current P/E ratio is -0.9.
What is the 52-week high for ENGN stock?
The 52-week high for Engene Therapeutics is $12.25. The current close of $1.76 is 85.6% below that high.
What is the 52-week low for ENGN stock?
The 52-week low for Engene Therapeutics is $1.40. The current close of $1.76 is 25.7% above that low.
Does ENGN stock pay dividends?
Engene Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for ENGN?
Engene Therapeutics's Debt / Equity ratio is 0.13.